LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
2 h agoKey statistics
2 h ago- Market cap
- $1.01T
- Enterprise value
- $1.04T
- P/E (TTM)
- 39.81
- Forward P/E
- 27.51
- P/E (annual)
- 48.75
- PEG
- 1.37
- P/B
- 38.29
- P/S (TTM)
- 13.93
- P/S (annual)
- 15.44
- EV / EBITDA
- 31.11×
- EV / Revenue
- 14.45×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.64%
- Dividend yield (TTM)
- 0.56%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.52
- Volatility (3M)
- 37.57%
Analyst ratings
2 h agoEarnings
2 h agoRelated news
2 h ago- Benzinga·5 d agocompanyEli Lilly To Present New Data Across Its Cardiometabolic Portfolio At American Diabetes Association's 86th Scientific Sessions
Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin
- Yahoo·5 d agocompanyEli Lilly shares edge higher after CVS expands coverage for Zepbound obesity drug (LLY)
Eli Lilly and Company (NYSE:LLY) shares gained about 1% in premarket trading Thursday after CVS Caremark announced it would add the company’s obesity treatment Zepbound to its preferred drug formulary. Lilly said the decision means all three of the largest pharmacy benefit managers in the United States will now provide coverage for the company’s full obesity medicine portfolio.
- Yahoo·5 d agocompanyEli Lilly (LLY) – Among the 10 Safe Stocks to Buy for the Long Term in 2026
Eli Lilly and Company (NYSE:LLY) is included among the 10 Safe Stocks to Buy for the Long Term in 2026. On May 26, BofA raised the firm’s price recommendation for Eli Lilly and Company (NYSE:LLY) to $1,251 from $1,133. It reiterated a Buy rating on the shares. The firm said it expects Lilly’s future revenue […]
- Yahoo·5 d agocompanyEli Lilly (LLY) Unveils Obesity Data That Could Raise The Bar For The Entire Industry
With a five-year EPS forecast of 28.38%, Eli Lilly and Company (NYSE:LLY) is among the 12 Best Future Stocks to Buy Right Now. On May 21, Eli Lilly and Company (NYSE:LLY) reported pivotal Phase 3 data for retatrutide that demonstrated weight loss of up to 26.1% at 80 weeks and more than 30% at 104 weeks in […]
- Yahoo·5 d agocompanyWhy Wolfe Research Remains Bullish on Eli Lilly and Company (LLY) and Its Obesity Pipeline
We recently compiled a list of the 10 Most Widely Held Stocks by Individuals in 2026. Eli Lilly and Company (NYSE:LLY) is also one of the most widely held stock by individuals. TheFly reported on May 21 that Wolfe Research maintained an Outperform rating on LLY and kept its $1,350 price target unchanged. The firm […]
- Yahoo·5 d agocompanySmall biotech firms quicker to 'latch onto' AI than big ones, says Tencent Healthcare President
Small biotech firms "latch onto" AI more quickly than bigger firms, the head of Chinese tech giant Tencent's healthcare division said on Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk and Eli Lilly have announced AI-related collaborations with technology firms.
- Yahoo·5 d agocompanyIs Eli Lilly Stock Outperforming the Nasdaq?
Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.
- Yahoo·5 d agocompanyCVS Caremark adds Zepbound and Foundayo to formulary
The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options
